Opiant Pharmaceuticals, Inc. Reports Fiscal Fourth Quarter

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Opiant Pharmaceuticals, Inc. Reports Fiscal Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update

SANTA MONICA, Calif., Oct. 31, 2016 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (OTCQB:OPNT), a specialty pharmaceutical company developing pharmacological treatments for substance use, addictive and eating disorders, today reported financial results for the fiscal fourth quarter and year ended July 31, 2016.

“The fourth quarter was one of continued progress and development at the company,” said Roger Crystal, M.D., Chief Executive Officer of Opiant. “In 2017, we look forward to increased demand for NARCAN® Nasal Spray, adding to our intellectual property portfolio and developing treatments, including for Binge Eating Disorder and Bulimia Nervosa.”

Fourth Quarter 2016 and Recent Highlights

  • A study published in The Journal of Clinical Pharmacology confirmed NARCAN® Nasal Spray’s (NARCAN) concentrated formulation rapidly delivers an effective naloxone dose.  
  • Health Canada granted approval to NARCAN.
  • Opiant’s commercial partner, Adapt Pharma Limited (“Adapt”), announced NARCAN’s coverage with California’s Medi-Cal program.
  • U.S. Food and Drug Administration (FDA) Joint Meeting endorsed commitment to higher doses and broader access for naloxone to help in fight against opioid overdose.
  • Filed a second NARCAN patent for listing in the FDA Orange Book to offer product exclusivity until 2035.
  • Opiant licensed a heroin vaccine from Walter Reed Army Institute of Research and National Institute on Drug Abuse, a division of the National Institutes of Health.

Clinical Program Update

Opiant develops treatments for substance abuse, addictive and eating disorders. Opiant expects to achieve the following milestones in fiscal year 2017:

  • 1H17: Report top-line results of the Phase II study in patients with Cocaine Use Disorder.
  • 1H17: Collaborate with other parties and initiate a study in developing a treatment for patients with Binge Eating Disorder.
  • 1Q17: Evaluate use of a nasal opioid antagonist and initiate a study for patients with Bulimia Nervosa.

Financial Results

Year ended July 31, 2016 compared to year ended July 31, 2015

For the year ended July 31, 2016, Opiant reported a net loss of $7.814 million, or $4.09 per basic and fully-diluted share, compared to a net loss of $7.038 million, or $3.88 per basic and fully-diluted share, for the year ended July 31, 2015. The increased net loss was due primarily to the increase in general and administrative expenses, particularly stock-based compensation. The increase was offset by an increase in revenues and a decrease in research and development expenses during the year ended July 31, 2016. 

Research and development expense in the year ended July 31, 2016, was $1.747 million compared to $2.415 million for the year ended July 31, 2015. General and administrative expense was $15.571 million in the year ended July 31, 2016, compared to $6.035 million for the year ended July 31, 2015. The decrease in research and development expenses was primarily due to decreased spending for Opiant’s opioid overdose reversal treatment product, now known as NARCAN. The increase in general and administrative expenses was primarily due to an increase in stock-based compensation, partially offset by decreases in professional fees, consulting costs and non-stock based officer’s compensation.

For the year ended July 31, 2016, Opiant reported revenue of $9.898 million, compared to $1.55 million for the year ended July 31, 2015. The increase in revenue during the year ended July 31, 2016 was in part the result of recognizing $4.8 million of revenue from the sale of net profit interests with respect to the Company’s opioid overdose reversal treatment, now known as NARCAN. The revenue from these sales was recognized during the year ended July 31, 2016 because either the investments in net profit interests did not contain an option to exchange the net profit interests for shares of the Company’s common stock or the product was approved by the FDA and marketed, which negated each relevant investor’s option to exchange its net profit interests for shares of common stock of the Company, and the research and development work related to the product was completed as of July 31, 2016. The Company also recognized $5.097 million of revenue derived from its license agreement with Adapt during the year ended July 31, 2016, which included a $2 million milestone payment received as a result of the FDA’s approval of NARCAN for the emergency treatment of known or suspected opioid overdose and a $2.5 million milestone payment received as a result of the first commercial sale of NARCAN, both of which are milestones set forth in the Company’s license agreement with Adapt.

About Opiant Pharmaceuticals, Inc.

Opiant Pharmaceuticals, Inc., is a specialty pharmaceutical company developing pharmacological treatments for substance use, addictive and eating disorders. Over 45 million people in the U.S. have one of these disorders. The National Institute on Drug Abuse (NIDA), a division of the National Institutes of Health (NIH), describes these disorders as chronic relapsing brain diseases which burden society at both the individual and community levels. With its innovative opioid antagonist nasal delivery technology, Opiant is positioned to become a leader in these treatment markets. Its first product, NARCAN® Nasal Spray, is approved for marketing in the U.S. by the company’s partner, Adapt Pharma Limited. Currently, Opiant is developing opioid antagonists for the treatment of substance use, addictive and eating disorders, with a near term focus on Cocaine Use Disorder and Binge Eating Disorder. For more information please visit: www.opiant.com .

Forward-Looking Statements

This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” or “continue” or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. In evaluating these statements, you should specifically consider various factors. These and other factors may cause our actual results to differ materially from any forward-looking statement. We undertake no obligation to update any of the forward-looking statements after the date of this press release to conform those statements to reflect the occurrence of unanticipated events, except as required by applicable law.

Financial tables to follow

  

Opiant Pharmaceuticals, Inc.
(formerly Lightlake Therapeutics Inc.)
Balance Sheets
As of July 31, 2016 and 2015
 
    July 31,     July 31,  
    2016     2015  
             
Assets                
Current assets                
Cash and cash equivalents   $ 1,481,393     $ 434,217  
Accounts receivable     312,498       -  
Prepaid insurance     62,404       33,143  
Total current assets     1,856,295       467,360  
                 
Other assets                
Computer equipment (net of accumulated amortization of $1,016 at July 31, 2016 and $0 at July 31, 2015)     6,521       -  
Patents and patent applications (net of accumulated amortization of $8,388 at July 31, 2016 and $7,015 at July 31, 2015)     19,062       20,435  
                 
Total assets   $ 1,881,878     $ 487,795  
                 
Liabilities and Stockholders' Deficit                
Liabilities                
Current liabilities                
Accounts payable and accrued liabilities   $ 140,584     $ 315,460  
Accrued salaries and wages     3,681,250       3,129,060  
Note payable     165,000       -  
Deferred revenue     250,000       -  
Due to related parties     -       130,000  
Total current liabilities     4,236,834       3,574,520  
                 
Deferred revenue     2,350,000       5,300,000  
Total liabilities     6,586,834       8,874,520  
                 
Stockholders' deficit                
Common stock; par value $0.001; 1,000,000,000 shares authorized;                
1,992,433 shares issued and outstanding at July 31, 2016 and 1,841,866 shares issued and outstanding at July 31, 2015     1,992       1,842  
Additional paid-in capital     56,478,394       44,982,519  
Accumulated deficit     (61,185,342 )     (53,371,086 )
Total stockholders' deficit     (4,704,956 )     (8,386,725 )
Total liabilities and stockholders' deficit   $ 1,881,878     $ 487,795  
                 

The accompanying notes are an integral part of these financial statements.

   

Opiant Pharmaceuticals, Inc.
(formerly Lightlake Therapeutics Inc.)
Statements of Operations
For the years ended July 31, 2016 and 2015
 
    For the  
    Year Ended  
    July 31,  
    2016     2015  
             
Revenues                
Royalty and licensing revenue   $ 5,097,595     $ 800,000  
Treatment investment revenue     4,800,000       750,000  
      9,897,595       1,550,000  
                 
Operating expenses                
General and administrative     15,571,080       6,034,520  
Research and development     1,747,077       2,414,973  
Selling expenses     317,917       -  
Total operating expenses     17,636,074       8,449,493  
                 
Loss from operations     (7,738,479 )     (6,899,493 )
                 
                 
Other income (expense)                
Interest expense     (11,890 )     (28,232 )
Loss on foreign exchange     (63,887 )     (110,148 )
Total other income (expense)     (75,777 )     (138,380 )
                 
Loss before provision for income taxes     (7,814,256 )     (7,037,873 )
                 
Provision for income taxes     -       -  
                 
Net loss   $ (7,814,256 )   $ (7,037,873 )
                 
Loss per share of common stock:                
Basic and diluted   $ (4.09 )   $ (3.88 )
Weighted average common stock outstanding                
Basic and diluted     1,910,489       1,813,069  
                 

The accompanying notes are an integral part of these financial statements.

CONTACT INFORMATION: Corporate Contact: Investor.relations@opiant.com Media Relations and Investor Relations: Scott Stachowiak Assistant Vice President RussoPartners/LLC Scott.Stachowiak@russopartnersllc.com (646) 942-5630

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Shenzhen's Vision Unveiled: APEC 2026 Promo Debut

Updated Category News Views 410

Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...

Continue Reading
Championing Change: USTA Mid-Atlantic Gala's Impact

Updated Category News Views 277

A Night to Remember: USTA Mid-Atlantic's Gala Who would've thought tennis could wield such transformative power? This ain't your average sport gala. Last Saturday, a crowd of over 300 gathered at the Ritz-Carlton Tysons Corner for the USTA Mid-Atlantic Foundation's 2026 Tennis Creates Gala. Hosted by the formidable Malika Andrews, this event wasn't just a fancy...

Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 235

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading
JOYEE N01 Debuts Globally with First 2,000 Deliveries

Updated Category News Views 284

JOYYE N01 Breaks into the Global Market Now, here we go, folks—a Chinese car with ambitions bigger than the Sahara. On October 28, the JOYEE N01 rolled off the assembly line and into the international scene with a lot of fanfare at FAW's Yancheng Branch. Mark my words, this isn't just another model trying to strut into the global auto arena. This event delivered the...

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 318

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 103

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
KINGRVER Boosts RV Comfort with New Water Heater Lineup

Updated Category News Views 233

An Upgrade for the Open Road In the land of RV living, comfort is king—or in this case, KINGRVER. Dropping affordable upgrades for water heaters into the world of RVs, KINGRVER's CT6 lineup is like a warm hug on a chilly campsite morning. Whether you've pulled up to a wooded retreat or parked under the vast desert sky, having dependable hot water shouldn't be a gamble....

Continue Reading
Kayla Harrison Dominates UFC 334, Earns Big Win

Updated Category News Views 0

Kicking off UFC 334 with a bang, Kayla Harrison didn't just step into the Octagon—she bulldozed her way through Amanda Nunes to retain her Women's Bantamweight Championship. This showdown didn't just electrify New York's Madison Square Garden, it shook the entire MMA landscape. Harrison, the face of Monster Energy's athlete roster, wasn't content with just defending her...

Continue Reading
Beef 'O' Brady's Expands Into Tuscaloosa Market

Updated Category News Views 203

A New Player in Town: Beef 'O' Brady's Lands in Tuscaloosa Listen up, sports fans and pub grub lovers of Tuscaloosa! Beef 'O' Brady's just kicked down the doors and expanded its reach, opening a location smack on McFarland Boulevard. The place threw open its doors on October 26 and is set to make waves in the local scene, driven by the dedicated hands of Mitul Patel and...

Continue Reading
Princess Cruises Launches New Era at Celebration Key

Updated Category News Views 153

Never thought I'd see the day when a cruise ship docking would stir such excitement, but here we are. The Star Princess has made its grand debut at Celebration Key, the latest jewel in Princess Cruises' crown. And they're going all out with Bahamian flair—something about a Junkanoo band and beach art that would make even the crustiest sailor crack a smile. Inaugural Fun...

Continue Reading

Top 5 Most Recently Viewed Articles

Fokus Mining Corporation Pursues $1.5 Million Funding Initiative

Updated Category News Views 194

Fokus Mining Corporation Reveals New Funding Initiative Fokus Mining Corporation (TSX.V: FKM) and OTCQB: FKMCF has announced an exciting plan to raise $1.5 million through a private placement. This move is particularly important as it highlights the company's dedication to advancing its projects and boosting its operational capabilities. Overview of the Private Placement...

Continue Reading
Empowering Investors: Lions Gate Entertainment Corp. Class Action

Updated Category News Views 102

Understanding the Investigation into Lions Gate Entertainment Corp. Lions Gate Entertainment Corp. is facing serious scrutiny due to concerns about possible misrepresentation of crucial business information to shareholders. This situation has sparked a thorough examination of their practices, especially following a recent lawsuit filed against the company. Details of the...

Continue Reading
Revolutionary Tool Simplifies Muriatic Acid Application for Pools

Updated Category News Views 137

Innovative Solution for Pool Maintenance Maintaining a clean and attractive swimming pool is essential for many homeowners. One common challenge faced during pool maintenance is dealing with stubborn stains that can mar the pool's beauty. To address this issue, an inventive mind has introduced a unique tool known as STICK-A-STAIN, designed specifically for applying...

Continue Reading
Landsnet Reports Strong Half-Year Results with Future Growth in Sight

Updated Category News Views 163

Landsnet's Half-Year Financial Performance Overview Landsnet recently released its financial report for the period ending in June 2025, showing noteworthy progress. The company reported a profit of USD 11.5 million, supporting its robust standing in the market. Key Financial Highlights The interim financial results indicate a decrease in profit compared to last year,...

Continue Reading
KabaFusion and Tennr Join Forces to Transform Home Infusion Care

Updated Category News Views 222

KabaFusion and Tennr Join Forces to Transform Home Infusion Care Strategic Partnership Uses AI to Advance Patient Care, Empower Clinicians, and Optimize Home Infusion Services KabaFusion, a leading name in home infusion, has announced its strategic partnership with Tennr, a cutting-edge healthcare technology firm known for automating referral-based care. This...

Continue Reading